Chronic Administration of Cannabinoid Receptor 2 Agonist (JWH-133) Increases Ectopic Ovarian Tumor Growth and Endocannabinoids (Anandamide and 2-Arachidonoyl Glycerol) Levels in Immunocompromised SCID Female Mice

• Κύριοι συγγραφείς: Henry L. Blanton (Συγγραφέας), Melissa C. McHann (Συγγραφέας), Haley De Selle (Συγγραφέας), Canice Lei Dancel (Συγγραφέας), Jose-Luis Redondo (Συγγραφέας), Deborah Molehin (Συγγραφέας), Nadezhda A. German (Συγγραφέας), Scott Trasti (Συγγραφέας), Kevin Pruitt (Συγγραφέας), Isabel Castro-Piedras (Συγγραφέας), Josée Guindon (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Frontiers Media S.A., 2022-02-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Cannabinoid-based therapies are increasingly being used by cancer patients to treat chemotherapy-induced nausea and vomiting. Recently, cannabinoids have gained increased attention for their effects on cancer growth. Indeed, the effect of CB2 (JWH-015, JWH-133) agonists on breast cancer models have...